Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03393936
Other study ID # CCT301-mRCC01; Phase I/II
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date March 26, 2018
Est. completion date June 30, 2023

Study information

Verified date October 2021
Source Shanghai PerHum Therapeutics Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a two arm, open-label, dose escalation and dose expansion clinical study to evaluate the safety and efficacy of infusion of autologous CCT301-38 or CCT 301-59 T cells in adult subjects with relapsed and refractory stage IV metastatic renal cell carcinoma.Subjects with ROR2 positive biopsy will receive CCT301-59. Subjects with AXL positive biopsy that are ROR2 negative will receive CCT301-38.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 66
Est. completion date June 30, 2023
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Men or women aged 18~70 years old. 2. Patients are diagnosed as refractory / recurrent, Stage IV renal cell carcinoma by histological method with FDG PET signal > 3 SUV in measurable metastatic lesion. 3. Patients with at least two metastatic lesions, including one measurable metastatic tumor lesion >10 mm measurable by CT. 4. Tumor tissues samples confirmed CCT301 target positive IHC. Patient with histological biopsy. - tumor tissue with greater than or equal to 50% positive staining by IHC method for ROR2 ; - tumor tissue with greater than or equal to 50% positive staining by IHC method for AXL that is ROR2 negative. 5. Expected survival =12 weeks. 6. ECOG 0-1 7. Adequate organ function as documented by: - ANC=1.9X10^9/L - PLT=100x10^9/L - Hb=9.0g/dL - rCCR=50ml/min - ALT and AST=2.5ULN; for liver metastasis, ALT and AST =5ULN - Serum TBiL=3.0mg/dL, TBiL=2.5ULN 8. PT: INR < 1.7 or extended PT to normal value < 4s 9. Adequate venous access for venous blood collection, and no other contraindication of blood cell separation 10. Patients with willingness to be in this study and able to provide informed consent 11. Capable of receiving treatment and follow up, included patients are required to receive treatment in the enrolled centre 12. Women of childbearing age are required to take acceptable measures to minimize the possibility of pregnancy during whole session. Women of childbearing age must have negative results of serum or urine tests within 24 hours prior to infusion. Women patients must not be in lactation; 13. Immunological detection Exclusion Criteria: 14. Pregnant women or women in lactation. 15. Active HBV or HCV infection. 16. HIV/AIDS infection. 17. Active infection 18. Previously suffered from diseases or concurrent diseases as follows: 19. Patients confirmed as severe autoimmune diseases in long-term (over 2 months) need of systemic immune inhibitors (steroid) or as immune-mediated symptomatic diseases including ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), autoimmune vasculitis (for example, Wegener's granulomatosis) 20. Patients with previous diagnosis as motor neuron disease caused by autoimmunity 21. Patients previously suffered from toxic epidermal necrolysis (TEN) 22. Patients with any mental diseases including dementia, mental status change that may impinge the understanding and performance of informed consent and related questionnaire 23. Patients with severe, uncontrollable diseases judged by investigator that may hinder them receiving this treatment 24. Patients with other previously active malignant tumors including basal or squamous skin cancer, superficial bladder cancer, and in situ breast carcinoma within 5 years who had been completely cured without the need of follow-up treatment are not excluded. 25. Ongoing treatment using systemic steroid or steroid inhalants. 26. Previous treatment used gene/cell therapy products. 27. Previous experience of immunotherapies including CIK, DC, DC-CIK, LAK for the treatment of cancer. 28. Allergic to immunotherapies or related drugs 29. Patients in need of treatment for heart failure with =2 NYHA or for poor controlled hypertension. 30. Patients with unstable or active peptic ulcer or alimentary tract hemorrhage. 31. Patients with previous organ transplantation or ready for organ transplantation. 32. Patients in need of anticoagulant therapy treatment (warfarin or heparin) 33. Patients judged by investigators as not appropriate for this study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
CCT301-38
Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-38. During CCT301-38 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-38 by intravenous (IV) injection.
CCT301-59
Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-59. During CCT301-59 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-59 by intravenous (IV) injection.

Locations

Country Name City State
China Shanghai Public Health Clinical Center Shanghai Shanghai

Sponsors (2)

Lead Sponsor Collaborator
Shanghai PerHum Therapeutics Co., Ltd. Shanghai Public Health Clinical Center

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase I Safety (Incidence of adverse events defined as dose-limiting toxicities(DLT) Incidence of adverse events defined as dose-limiting toxicities (DLT) Up to 28 days from cell infusion
Primary Phase II Objective Response Rate Objective Response Rate of confirmed complete and partial remission by independent radiology review RECIST (1.1) Up to 9 months from cell infusion
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04987203 - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Phase 3
Recruiting NCT06391879 - Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Completed NCT02853344 - Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) Phase 2
Terminated NCT04088500 - A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma Phase 2
Completed NCT05070637 - Circulating Tumor Cell Reducing No-touch Nephrectomy N/A
Active, not recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Not yet recruiting NCT06049030 - A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT01358721 - Phase I Biomarker Study (BMS-936558) Phase 1
Active, not recruiting NCT04503148 - Anesthesia and Cancer Study: Renal Cell Carcinoma N/A
Completed NCT02386826 - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Phase 1
Not yet recruiting NCT05808608 - A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma Phase 1/Phase 2
Withdrawn NCT03323710 - Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma Phase 2
Not yet recruiting NCT02787915 - DC1s-CTL Cellular Therapy for Renal Cell Carcinoma Phase 1/Phase 2